Management of classic congenital adrenal hyperplasia (CAH) can be a lifelong balancing act, but the most feared life-threatening complication is an acute adrenal insufficiency, also known as an ...

Congenital adrenal hyperplasia (CAH) is a rare genetic condition present from birth. A person with CAH lacks one of the enzymes needed for their adrenal glands to work correctly. Sitting above the ...

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...

Neurocrine Biosciences’ newest educational campaign wants frustrated congenital adrenal hyperplasia patients to ask, “What the C@H?!” Neurocrine unveiled the campaign this week, not long after ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal ...

Congenital adrenal hyperplasia (CAH) is a group of inherited conditions in which the adrenal glands cannot make certain hormones, most commonly due to a deficiency of the enzyme 21-hydroxylase. This ...

Phyllis Speiser is emeritus professor of pediatrics at Zucker School of Medicine at Hofstra-Northwell and associate investigator at The Feinstein Institute for Medical Research of Northwell Health.

Please provide your email address to receive an email when new articles are posted on . Crinecerfont allowed lower glucocorticoid doses for children with congenital adrenal hyperplasia at 28 weeks.

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating ...